Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT.
Sébastien MuléJulia ChalayeFrançois LegouArthur TenenhausJulien CalderaroAthena Galletto PregliascoAlexis LaurentRym KharratGiuliana AmaddeoHélène RegnaultVania TacherHicham KobeiterEmmanuel IttiAlain LucianiPublished in: European radiology (2020)
• In patients with resectable HCC, the quantitative analysis of the HBP tumor enhancement in Gd-BOPTA-enhanced MRI (LLCER) accurately identifies moderately-poorly differentiated and/or MVI-positive HCCs. • After surgical resection for HCC, patients with LLCER - 4.72% or less had significantly poorer recurrence-free survival than patients with LLCER superior to - 4.72%. • Gd-BOPTA-enhanced MRI with delayed HBP images may be suggested as part of pre-surgery workup in patients with resectable HCC.
Keyphrases
- free survival
- pet ct
- contrast enhanced
- positron emission tomography
- locally advanced
- magnetic resonance imaging
- liver metastases
- computed tomography
- magnetic resonance
- diffusion weighted imaging
- minimally invasive
- pet imaging
- coronary artery bypass
- deep learning
- rectal cancer
- genome wide
- squamous cell carcinoma
- convolutional neural network
- optical coherence tomography
- radiation therapy
- gene expression
- coronary artery disease
- machine learning
- dna methylation
- surgical site infection
- atrial fibrillation